All In Biotech

Free tool

FAERS Monitor: Samsca

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022275 or its brand name (Samsca, Tolvaptan). Reports on generic versions are filed under their own applications.

Reports

14,926

Serious

11,890

80% of reports

Hospitalization

4,752

Death reported

3,255

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,042
  • thirst1,011
  • off label use888
  • renal impairment884
  • cardiac failure828
  • product dose omission issue779
  • pollakiuria602
  • wrong technique in product usage process535
  • product use in unapproved indication501
  • underdose498
  • dehydration481
  • no adverse event481
  • blood creatinine increased467
  • inappropriate schedule of product administration460
  • polyuria456

Reports by year received

View as table
YearReports
20081
200914
201043
2011128
2012345
2013430
2014357
2015531
2016744
2017889
20181,079
20191,238
2020761
20211,018
20221,022
20231,068
20241,521
20252,027
20261,710

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,233 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
thirstSignal1,01184.579.478,666
polyuriaSignal45683.075.734,837
pollakiuriaSignal60220.619.111,083
renal impairmentSignal88415.014.011,440
cardiac failureSignal82814.713.710,469
blood creatinine increasedSignal46710.19.33,825
underdoseSignal4989.78.93,851
dehydrationSignal4815.14.71,584
no adverse eventSignal4813.73.4972
product dose omission issueSignal7793.73.51,579
wrong technique in product usage processSignal5353.73.41,073
inappropriate schedule of product administrationSignal4603.63.3868
product use in unapproved indicationSignal5012.92.6607
death1,0421.71.6316
off label use8881.41.3119

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.